CD8A and cancer: Intermittent administration of copanlisib led to increased infiltration of activated CD8+ T cells and macrophages, enhanced CD8+/Treg and M1/M2 macrophage ratios, and demonstrated significant antitumor activity, although the in vitro resistance of cancer cells to PI3K inhibition.